Publications found:
251,903
Sort by:
Hemostasis Diagnostics Market Leading Suppliers and Emerging Market Entrants
US$ 2,000.00
This report presents analyses of major current and emerging suppliers of hemostasis products, including: The 2010 sales estimates Market shares Product portfolios Marketing tactics Technological know-how New products in R&D Collaborative arrangements Business strategies. Contains 45 pages
February 2012
45 pages
Japan- Pharma Fact Sheet
US$ 400.00
Looking at the great deal of business interest in the Japan Pharmaceutical space, we have recently published a report on Japan Pharma - "Japan Pharma - Factsheet". The 10 page report has som...
February 2012
8 pages
DAIICHI SANKYO - Growth Story Remains Intact!
US$ 90.00
... rating on Daiichi Sankyo (DS) while revising down 12-months TP to ¥1,850 on account of incorporating likely impact of Ranbaxy settlement cost and tax reforms in Japan. Going forward ...
February 2012
2 pages
RANBAXY - Teva Partnership Hurts
US$ 140.00
... the unexpectedly high payment of ~$150m to Teva under the Lipitor generic agreement. Ranbaxy generated ~$300m from generic Lipitor that ... (1) Daiichi-Ranbaxy likely to become the largest generic company in Japan generics market (2) leveraging of Ranbaxy’s emerging market infrastructure (especially India) to ...
February 2012
6 pages
VIVUS: Potential for Adding More Weight in April
US$ 140.00
... safety profile. With the risk of generics, commercial potential of Avanafil worth... The upside could be more in case of a buyout, favorable licensing deal, ... approval time in April… For more details, please read our report released on February 24, 2012 on VVUS, titled “Potential for Adding More Weight in April”
February 2012
9 pages
Assessment of the Asia-Pacific In-Vitro Diagnostic (IVD) Market
US$ 800.00
... the healthcare facilities. The segments expected to witness high growth in the Asia IVD market are molecular diagnostics, point-of-care tests and self ... issues. Why should the report be purchased? Our report ‘Assessment of the Asia-Pacific In-Vitro Diagnostic (IVD) Market’ provides an overview of the IVD ...
February 2012
25 pages
Life Science & Chemical Instrumentation Market (2011 - 2016) Global Trends, End User & Competitive Analysis
US$ 5,650.00
... require quality instruments with high throughput capacity. All these factors are driving the life science and chemical instrumentation market. The global life science and chemical instrumentation market ... Life science and chemical instruments instrumentation market, by end-users: Pharmaceuticals and biopharmaceutical companies Research laboratories Academic institution Food and beverages Environmental Others Life science and chemical instruments instrumentation ...
February 2012
391 pages
Medicated Skin Care in Australia
US$ 990.00
Value growth of 4% in medicated skin care in 2011 was largely generated by changes in Australia’s demographic mix, particularly in relation to age. Succinctly, growth was driven by ... grew by 8%, making nappy rash the fastest growing niche in medicated skin care. Euromonitor International's Medicated Skin Care in Australia report offers a comprehensive guide to the size and shape ...
February 2012
34 pages
China’s Guidebook for Pharmaceutical Patent Protection
US$ 1,495.00
Description China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2011, sales on the Chinese drug market have reached RMB 1550 billion (about US...
February 2012
230 pages
Emerging Special Hematology Tests and Flow Cytometry Applications
US$ 1,480.00
The report presents an overview of the clinical significance and market needs for major hematology and flow cytometry procedures, including listings of companies developing or marketing new technologies and products. Contains 85 pages
February 2012
85 pages
Medicated Skin Care in Indonesia
US$ 990.00
... awareness of the presence of some medicated skin care products to treat their conditions in the first place. Euromonitor International's Medicated Skin Care in Indonesia report offers a comprehensive guide to the ... and Allergy Remedies, Paediatric Digestive Remedies, Paediatric Medicated Skin Care, Pharyngeal Preparations, Standard Eye Care, Sticking Plasters/Adhesive Bandages, Systemic Analgesics, Topical ...
February 2012
35 pages
REGENERON: Marching Towards Profitability!
US$ 140.00
... Lucentis)! REGN should finally evolve from a Rising Star to become a profitable Biotech from 2012 onwards on the strength of its pipeline and ... , please read our report released on February 17, 2012 on REGN, titled “Marching Towards Profitability!”
February 2012
8 pages
Medicated Skin Care in Azerbaijan
US$ 990.00
... within this area. Consequently, many consumers began to use medicated skin... Euromonitor International's Medicated Skin Care in Azerbaijan report offers a comprehensive guide to the size and shape ... and Allergy Remedies, Paediatric Digestive Remedies, Paediatric Medicated Skin Care, Pharyngeal Preparations, Standard Eye Care, Sticking Plasters/Adhesive Bandages, Systemic Analgesics, Topical ...
February 2012
28 pages
Medicated Skin Care in Uruguay
US$ 990.00
... medicated skin care products at a good and steady pace, producing sustained growth in volume and value sales across most of the category. Euromonitor International's Medicated Skin Care in Uruguay ... and Allergy Remedies, Paediatric Digestive Remedies, Paediatric Medicated Skin Care, Pharyngeal Preparations, Standard Eye Care, Sticking Plasters/Adhesive Bandages, Systemic Analgesics, Topical ...
February 2012
21 pages
Medicated Skin Care in Israel
US$ 990.00
... to strict regulations. Companies in Israel have recently realised the strong potential among the more profitable medical devices within medicated skin care products. There are many different products within medicated skin care. Lice treatment, for example, is highly influenced by sales of medical devices. Euromonitor International's Medicated Skin Care in Israel ...
February 2012
33 pages
Medicated Skin Care in Peru
US$ 990.00
... -income consumers. Despite this, generics are progressively... Euromonitor International's Medicated Skin Care in Peru report offers a comprehensive guide to the size and shape of the ... and Allergy Remedies, Paediatric Digestive Remedies, Paediatric Medicated Skin Care, Pharyngeal Preparations, Standard Eye Care, Sticking Plasters/Adhesive Bandages, Systemic Analgesics, Topical ...
February 2012
34 pages
Emerging Opportunities in Cancer Nucleic Acid Testing
US$ 1,160.00
The report presents an overview of the clinical significance and market needs for major tumor markers, as well as listings of companies developing and marketing NAT technologies and products for cancer testing. Contains 45 pages
February 2012
45 pages
Future Infectious Disease Nucleic Acid Testing
US$ 2,000.00
This 360-page report presents an overview of the clinical significance and market needs for major infectious diseases, as well as extensive listings of companies developing and marketing molecular diagnostic technologies and products. Contains 360 pages and 20 tables
February 2012
360 pages
Tumor Marker Diagnostic Technologies and Their Potential Market Applications
US$ 1,480.00
... potential applications of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, flow cytometry and biosensors or tumor marker diagnostic testing. Review of competing/complementing technologies, such as CT, MRI, NMR, PET and photonics spectroscopy. Contains 110 pages
February 2012
110 pages
Future French Tumor Marker Testing Market Outlook
US$ 4,320.00
... Comprehensive 585-page analysis of the French tumor marker testing market. Major issues pertaining to the French laboratory practice, as well as key ... volume and sales forecasts for over 40 tumor markers performed in French hospitals and commercial laboratories. Placements and installed base of automated ...
February 2012
585 pages
Future German Tumor Marker Testing Market Outlook
US$ 4,320.00
... Comprehensive 585-page analysis of the German tumor marker testing market. Major issues pertaining to the German laboratory practice, as well as key ... volume and sales forecasts over for 40 tumor marker performed in German hospitals, commercial laboratories and physician offices. Placements and installed ...
February 2012
585 pages
Future Italian Tumor Marker Testing Market Outlook
US$ 4,320.00
... Comprehensive 570-page analysis of the Italian tumor marker testing market. Major issues pertaining to the Italian laboratory practice, as well as key ... volume and sales forecasts for over 40 tumor marker performed in Italian hospitals and commercial laboratories. Placements and installed base of automated ...
February 2012
570 pages
Future Japanese Tumor Marker Testing Market Outlook
US$ 5,360.00
Highlights Comprehensive 590-page analysis of the Japanese tumor marker testing market. Major issues pertaining to the Japanese laboratory practice, as well as key ... , lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. Ten-year test volume and sales forecasts over for ...
February 2012
590 pages
Future Spanish Tumor Marker Testing Market Outlook
US$ 4,320.00
Highlights Comprehensive 565-page analysis of the Spanish tumor marker testing market. Major issues pertaining to the Spanish laboratory practice, as well as key ... , lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. Ten-year test volume and sales forecasts over for 40 ...
February 2012
565 pages
Future UK Tumor Marker Testing Market Outlook
US$ 4,320.00
... leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. Ten-year test volume and sales forecasts over for ... base of automated and semi-automated analyzers used for tumor marker testing. Current instrumentation technologies and feature comparison of leading analyzers. ...
February 2012
575 pages
Future US Tumor Marker Testing Market Outlook
US$ 6,960.00
... leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. Ten-year test volume and sales forecasts over for ... base of automated and semi-automated analyzers used for tumor marker testing. Current instrumentation technologies and feature comparison of leading analyzers. ...
February 2012
620 pages
Future Japanese Nucleic Acid Testing Market Outlook
US$ 6,000.00
Highlights Comprehensive 850-page market segmentation analysis of the Japanese NAT market. Major issues pertaining to the Japanese NAT laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An ...
February 2012
850 pages
Future Spanish Nucleic Acid Testing Market Outlook
US$ 4,720.00
Highlights Comprehensive 850-page market segmentation analysis of the Spanish NAT market. Major issues pertaining to the Spanish NAT laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An ...
February 2012
850 pages
Future UK Nucleic Acid Testing Market Outlook
US$ 4,720.00
... comparison of automated and semiautomated analyzers. Sales and market shares of leading suppliers. Over 60 specific opportunities for NAT instruments, test systems, IT and auxiliary products. Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing ...
February 2012
855 pages
Future US Nucleic Acid Testing Market Outlook
US$ 6,720.00
... comparison of automated and semiautomated analyzers. Sales and market shares of leading suppliers. Over 60 specific opportunities for NAT instruments, test systems, IT and auxiliary products. Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing ...
February 2012
880 pages
Emerging Tumor Markers and Companies Developing Innovative Technologies and Products
US$ 2,280.00
... Factors Lymphokines Immunohistochemical Stains. Overview of the clinical significance and market needs for both current and emerging tumor markers. Extensive listings of companies, universities and research centers developing or marketing new technologies, products, and applications. Contains 260 pages ...
February 2012
260 pages
Leading Nucleic Acid Testing Market Players
US$ 2,000.00
This 120-page report presents insightful analyses of current and emerging suppliers of NAT products, including: The 2010 Sales Product portfolio Marketing tactics Technological know-how New products in R&D Collaborative arrangements Business strategies Contains 120 pages
February 2012
120 pages
Future French Nucleic Acid Testing Market Outlook
US$ 4,720.00
Highlights Comprehensive 850-page market segmentation analysis of the French NAT market. Major issues pertaining to the French NAT laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An extensive ...
February 2012
850 pages
Future German Nucleic Acid Testing Market Outlook
US$ 4,720.00
Highlights Comprehensive 850-page market segmentation analysis of the German NAT market. Major issues pertaining to the German NAT laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An extensive ...
February 2012
850 pages
Furure Italian Nucleic Acid Testing Market Outlook
US$ 4,720.00
Highlights Comprehensive 850-page market segmentation analysis of the Italian NAT market. Major issues pertaining to the Italian NAT laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An ...
February 2012
850 pages
SUN PHARMA - Strong Base Business; Protonix Liability Not A Major Concern
US$ 140.00
We reiterate Sun Pharma as our Top Pick in the Indian pharma space after it’s higher ... to note that FY12 performance represents purely the base business with no one off upsides. Future growth ... new target price by applying a PE of 20x on FY13 base business earnings, valuing upcoming Para IVs at Rs. 25 per share ...
February 2012
6 pages
CIPLA, Withdrawing Positive Investment Alert - Structural Issues Loom Large
US$ 140.00
We withdraw our Positive Investment Alert post the dismal Q3 FY12 result that highlights Cipla’s structural issues. In addition, we believe that the supply of API of ... estimates by 18% and 12% in FY12 and FY13. We thus withdraw our Positive Investment Alert and reiterate our Market Perform rating with a target ...
February 2012
5 pages
VERTEX PHARMA - IFN-free Oral HCV Treatment – Vertex Not Out of the Race Yet!
US$ 140.00
... with G551D mutation), we see little risk to Vertex (VRTX) profitability for at least next three years ... of IL28B CC Genotype. Vertex has also accelerated the pace of developing IFN-free drugs to remain in the ... 14th Feb., 2012 on Vertex titled “IFN-free Oral HCV Treatment – Vertex Not Out of the Race Yet ...
February 2012
12 pages
